In grow-finish swine units receiving high-energy maize–soybean rations where mycotoxin loads fluctuate between 200 µg/kg and 800 µg/kg deoxynivalenol in incoming batches, Chaihuang Yigan Powder Veterinary Grade API is incorporated into dry premix intermediates rather than added directly to finished feed, because low mass fractions in bulk mixers produce unacceptable blend uniformity. The premix line operates under EU Regulation 183/2005/EC, Annex II hygiene provisions, with carryover and impurity control aligned to GB 13078-2017 for feed safety. For China-origin material, release follows the relevant monograph of the Chinese Veterinary Pharmacopoeia (2020 edition) where monographed. The API is pre-blended at 5 wt% to 10 wt% onto pregelatinised maize starch or calcium carbonate in a separate 100 L V-blender for 10 min before introduction into a 2,000 L single-ribbon paddle mixer. Finished inclusion is set at 1.0–3.0 kg premix per metric tonne complete feed, resulting in 50–300 g API per tonne, but field dosing is adjusted against baicalin marker recovery rather than raw powder mass because particle-size distribution shifts between botanical batches. The production sequence uses a 40-mesh (425 µm) oscillating screen before pre-blending; after addition to the main mixer, the batch is mixed for 8 min with coefficient of variation measured by riboflavin tracer at ≤5%. Moisture in the finished premix is held below 12% to prevent capillary bridging in screw feeders. Direct addition after pelleting is preferred because pellet conditioning at 70–85°C for 30–60 s can reduce extractable baicalin through thermal degradation; if the powder must be combined pre-pelleting, a 10 wt% hydrogenated vegetable oil coating is applied in a top-spray fluid bed to limit heat exposure. Terminal finished product types are dry top-dress premix, oral drench powder for automatic proportioning, and granulated feed premix packaged in 25 kg multi-wall paper bags with a polyethylene liner.

What Limits Solubility in Hard Water when Formulating Oral Solutions for Poultry?

Hard-water titration tests using 500 ppm CaCO₃ at 25°C show that untreated Chaihuang Yigan Powder forms cloudy suspensions unless the API is granulated with a volatile acid buffer system. Non-sterile oral solutions intended for administration via drinking water are tested for microbial quality per Ph. Eur. 5.1.4, and for uniformity of mass of single-dose preparations per Ph. Eur. 2.9.5 when filled into sachets. For EU marketing, the finished veterinary medicinal product falls under EU Regulation 2019/6, including transitional provisions for existing herbal products. In water-soluble powder, the API is blended with anhydrous citric acid at 10 wt% and sodium bicarbonate at 6 wt% to create a self-dispersing granule; API loading is 1.0 wt% to 3.0 wt% in the dry product. Field dilution at 1:1,000 yields 10–30 mg active powder per litre of drinking water, but published data for this exact herbal API in hard-water field conditions is limited, and dose confirmation should be based on total baicalin and saikosaponin recovery rather than solely on powder mass. Granulation is performed on a 5 L top-spray fluid-bed unit with inlet air temperature 55–65°C, atomising air pressure 1.0–1.5 bar, and a water-based binder solution of povidone K30 at 2 wt% solids. Drying continues until loss on drying is ≤3.0%. Disintegration and dissolution are checked in 900 mL purified water at 25°C using a USP type II paddle at 50 rpm; the target dispersion time is ≤3 min. The production bottleneck is hygroscopic caking at relative humidity above 60%, so sachet filling is run in an environment controlled at ≤40% RH and 18–22°C. Finished forms are water-soluble powder supplied in 100 g, 500 g, and 1 kg laminated aluminium sachets, effervescent granules, and liquid oral solution concentrates for proportioner dosing.

When Sterile Filtration Replaces Terminal Steam Sterilisation for Herbal Injectables

Injectable products based on clarified Chaihuang Yigan extract present a narrower processing window than oral powders because the baicalin glycoside fraction is stable in mildly acidic aqueous solution at pH 5.5–6.5 but degrades by ≥8% when exposed to 121°C for 15 min in forced-degradation studies; saikosaponin analogues hydrolyse under the same conditions. This behaviour excludes autoclaving unless the formulation contains stabilisers and is supported by terminal sterilisation validation under EMA/CVMP guidance. The sterile injectable route is developed under Ph. Eur. 5.1.1 methods of sterilisation and Ph. Eur. 2.6.1 sterility; cleanroom air classification follows ISO 14644-1:2015 Class 5 for filling and Class 7 for solution preparation. Residual solvent and impurity testing is conducted under VICH GL18 and VICH GL4. For export to the United States, current good manufacturing practice for finished pharmaceuticals applies under 21 CFR 210 and 21 CFR 211. The clarified liquid concentrate is diluted with water for injection to a final active powder equivalent of 1.0 wt% to 3.0 wt% adjusted by baicalin assay, with 0.3–0.5 wt% sodium chloride for isotonicity and 0.1 M citrate buffer to maintain pH. The final solution is passed through two filters: a 0.45 µm polypropylene prefilter and a 0.22 µm polyethersulfone sterilising-grade membrane; membrane integrity is tested by bubble point before and after filtration. Solution preparation is carried out in a stainless-steel jacketed vessel at 40°C under nitrogen sparging to limit oxidative discolouration. The solution is then cooled to 20°C, filtered, and filled into amber type I glass vials in laminar-flow Class 5. Fill volume is 10 mL or 20 mL. A major production-scale failure mode is filter plugging from reversible glycoside-polyphenol aggregation when the extract pH drifts above 6.5; therefore pH is measured in-line and adjusted before each filtration batch. Maximum filtration pressure differential is limited to 1.0 bar across the sterilising filter to prevent aggregate extrusion. Terminal products are sterile injectable solutions in 10 mL and 20 mL amber vials with bromobutyl rubber stoppers, filled under nitrogen headspace, suitable for intramuscular or slow intravenous administration according to approved veterinary labelling.

When companion animal tablet lines operate above 60% relative humidity, the flow properties of Chaihuang Yigan Powder deteriorate unless the raw blend is pre-dried at 40°C for 2 h before compression. Direct-compression lines handling 300–500 mg companion animal liver-support tablets require dry powder flowability sufficient to maintain press speed above 30 rpm without feed frame blockage. By blending the micronised API at 20 wt% to 35 wt% with spray-dried lactose monohydrate, microcrystalline cellulose at 30 wt%, crospovidone disintegrant at 2–5 wt%, and magnesium stearate at 0.5 wt%, the formulation achieves a compressibility index below 25% and an angle of repose below 35°. Uniformity of mass is tested according to Ph. Eur. 2.9.5, disintegration per Ph. Eur. 2.9.1 with a target of ≤15 min in water at 37°C, and friability per USP 1216 with a limit of ≤1.0% after 100 drum revolutions. Active marker content in finished tablets is verified by HPLC with validation parameters following VICH GL2. Compression is performed on a 16-station rotary press with precompression force of 5 kN and main compression force of 12–15 kN, producing tablets with hardness 50–80 N. Aqueous film coating is applied in a pan coater at 2–3% weight gain using HPMC E5 at 6 wt% solids, inlet air temperature 60°C, and pan speed 6–10 rpm. Finished product types are scored tablets for accurate splitting, hard gelatin capsules with semi-automatic capsule filling at 8,000 capsules/h, and powder for oral suspension in 30 mL and 60 mL bottles with graduated dropper.

Rumen-Stable Granule Carriers and Dry Cow Oral Powder Routes

For transition dairy cows and late-gestation beef cows, oral delivery of Chaihuang Yigan is complicated by ruminal dilution and potential degradation of uncoated powder in rumen fluid; therefore the API is embedded in a lipid-matrix granule. In 40 L jacketed high-shear granulators, the API at 10 wt% to 20 wt% is dispersed into molten hydrogenated vegetable oil at 58°C, then passed through an extruder-spheronizer to form 0.8–1.2 mm pellets. The lipid matrix slows release and protects the glycoside fraction from early ruminal degradation. Final oral drench powders are reconstituted at 200 g per 20 L water and administered by drench gun to groups of up to 50 animals; however, published data for the exact release rate in rumen-cannulated cattle is limited, and formulation release should be confirmed per individual production line. Feed-use intermediates are handled under ISO 22000:2018 and, where the product is a veterinary premix, under EU Regulation 2019/6; analytical method transfer follows VICH GL2 for assay and related substances. Residual moisture in the finished granule is limited to ≤5.0%, with water activity ≤0.6 to prevent mould growth. After extrusion-spheronisation, the granules are cooled in a vibratory fluid-bed cooler from 58°C to 25°C within 10 min to avoid lipid polymorphic transition that increases surface flaking. A final sieving step on a 1.2 mm and 0.8 mm double-deck screen removes fines; fines are recycled at ≤5 wt% of the batch to prevent over-wetting in subsequent batches. Packaging is conducted at ≤30% RH to avoid stickiness on the lipid surface. Finished forms are rumen-stable granules in 10 kg buckets, dry cow oral powder in premeasured 100 g water-soluble pouches, and oral drench suspension powder packaged in 1 kg bi-layer foil pouches.

Fatty Liver in Intensive Cyprinid and Tilapia Lines: Extrusion-Stable Premix Constraints

High-energy extruded diets for tilapia and carp at water temperatures of 26–30°C are associated with excessive hepatic lipid deposition; the inclusion of Chaihuang Yigan in the mash before extrusion must be avoided because the barrel temperature profile of 90°C, 110°C, 120°C across three zones degrades unprotected flavonoids. Instead, the API is microencapsulated in a fluidised bed Wurster coater with ethylcellulose N7 at a 10% coating level, producing particles with a mass median diameter of 180–250 µm. The coated particles are applied after extrusion during vacuum coating or as a top-dress premix. Published retention data for this specific Chaihuang Yigan coated configuration in twin-screw extruded tilapia pellets are limited; each production line should run a marker recovery study before commercial scale-up. Aquaculture feed safety is managed under ISO 22000:2018 and, for international shipments, hygiene requirements derived from Codex CAC/RCP 52-2003. The premix itself is non-medicated feed material in some jurisdictions; if a veterinary claim is made, the finished product must comply with EU Regulation 2019/6 or local registration. Mycotoxin control in plant carriers is verified against GB 13078-2017. The coated API is blended into the post-extrusion oil-coating mixture at 3 wt% to 5 wt% of the oil slurry, corresponding to 0.3–0.5 kg coated API per 1,000 kg finished pellets. For top-dress powder, a direct addition of 2–4 g per kg feed is used, but target dose is adjusted by baicalin content and species-specific feeding rate. Post-extrusion application uses a vacuum coater operated at −0.4 bar to −0.6 bar for 4–6 min, followed by a reverse-flow cooling conveyor to bring pellet surface temperature below 35°C before bagging. For top-dress powder, the coated API is mixed with defatted rice bran in a 500 L ribbon mixer for 10 min and packed in 25 kg paper bags with inner polyethylene liner. A production bottleneck is segregation during pneumatic conveying; dense-phase conveying at ≤2 bar is recommended over dilute-phase systems to preserve particle integrity.